Immunotherapy Weekly articles from November 2002

Immunotherapy Weekly archives from November 2002

Lack of natural 'antibiotics' in the skin may explain infections.(atopic dermatitis)
November 6, 2002... 2002 NOV 6 - (NewsRx.com & NewsRx.net) -- In a study published in the October 10, 2002, New England Journal of Medicine, scientists report that people with atopic dermatitis - the most common form of eczema - fail to produce germ-killing...

Researchers identify candidate vaccine.(Sjogren's syndrome vaccine)
November 6, 2002... 2002 NOV 6 - (NewsRx.com & NewsRx.net) -- Researchers at the Hospital for Sick Children (HSC), Toronto Western Hospital and the University of Toronto (U of T) have identified the protein that triggers the autoimmune response in Sjogren...

Autologous immunotherapy shown safe, effective.(for HIV control)
November 6, 2002... 2002 NOV 6 - (NewsRx.com & NewsRx.net) -- A clinical trial by researchers at the University of Medicine and Dentistry of New Jersey (UMDNJ) has shown a new autologous immunotherapy appears to be safe and effective treatment for controlling HIV....

New avenue of HIV damage found.(injury to T-cell zone damages immune system)
November 6, 2002... 2002 NOV 6 - (NewsRx.com & NewsRx.net) -- Researchers at the University of Minnesota have discovered a new process by which HIV damages the immune system. They demonstrated that the portion of lymph nodes called the T-cell zone is...

Combining ionizing radiation and radioimmunotherapy appears safe.(external beam radiotherapy and Zevalin for non-Hodgkin lymphoma treatment)(Brief Article)
November 6, 2002... 2002 NOV 6 - (NewsRx.com & NewsRx.net) -- Combining external beam radiotherapy and the immunotherapy drug Zevalin appears to be a safe and effective treatment for patients with some of the most common types of non-Hodgkin lymphoma, according to...

Dr. Sidney Pestka joins ADVR scientific advisory board.(Advanced Viral Research Corp.)(Brief Article)
November 6, 2002... 2002 NOV 6 - (NewsRx.com & NewsRx.net) -- Advanced Viral Research Corp. (ADVR) announced that Dr. Sidney Pestka has joined the company's scientific advisory board. Pestka, a recipient of the National Medal of Technology, brings decades...

Environmental tobacco smoke exposure during travel affects adults with asthma.
November 6, 2002... 2002 NOV 6 - (NewsRx.com & NewsRx.net) -- Environmental tobacco smoke (ETS) exposure has been linked to many adverse health effects, ranging from asthma exacerbation to eye irritation to lung cancer. According to a new study by the...

CEO announces services agreement with MedImmune.(BioReliance Corp. in agreement with MedImmune)(Brief Article)
November 6, 2002... 2002 NOV 6 - (NewsRx.com & NewsRx.net) -- BioReliance Corp. (BREL) announced that it has entered into a laboratory services agreement with MedImmune, Inc. Under the agreement, BioReliance will perform a range of assays for certain of...

Biopharmaceutical firm raises $3M.( Advanced Viral Research Corp.)
November 6, 2002... 2002 NOV 6 - (NewsRx.com & NewsRx.net) -- Advanced Viral Research Corp. (ADVR) announced the completion of a $3 million institutional financing transaction that enables the clinical studies of Product R in Israel to move forward. The...

FDA grants peanut allergy drug fast track status.(TNX-901 from Tanox Inc.)
November 6, 2002... 2002 NOV 6 - (NewsRx.com & NewsRx.net) -- Tanox, Inc., (Nasdaq:Tnox) announced that the U.S. Food and Drug Administration (FDA) has granted fast track status to TNX-901 for the treatment of patients with peanut allergies. Under the FDA...

Immunotherapeutic compound to be tested in animal model.(CEL-SCI Corp. to test CEL-1000 herpes protective agent)
November 6, 2002... 2002 NOV 6 - (NewsRx.com & NewsRx.net) -- CEL-SCI Corporation (CVM) announced an agreement with the Cincinnati Children's Hospital Medical Center (CHMR) of the University of Cincinnati, Ohio, to evaluate Cel-Sci's new compound CEL-1000...

Cell-based product developer receives $0.9 million immune system research grant from DARPA.(Aastrom Biosciences Inc.)
November 6, 2002... 2002 NOV 6 - (NewsRx.com & NewsRx.net) -- Aastrom Biosciences, Inc., (ASTM) announced that it was awarded approximately $897,000 of a collaborative grant by the Defense Advanced Research Projects Agency (DARPA) providing funding over an...

Patient recruitment target reached in pivotal trial of pemtumomab.(Antisoma PLC reaches recruitment quota for its Study of Monoclonal Antibody Radioimmunotherapy for ovarian cancer trial)
November 6, 2002... 2002 NOV 6 - (NewsRx.com & NewsRx.net) -- Antisoma plc, a biopharmaceutical company based in Britain, announced it has reached the target for patient recruitment in its pivotal phase III study of pemtumomab in ovarian cancer. Four hundred...

Enhanced tamper-resistant packaging introduced by Bayer.(Bayer Biological Products )
November 6, 2002... 2002 NOV 6 - (NewsRx.com & NewsRx.net) -- Bayer Biological Products (BP) has introduced enhanced tamper-resistant packaging in response to recent concerns about product tampering. The roll-out of seal tabs on all boxes containing Gamimune...

Angiotech initiates phase II study of micellar paclitaxel for injection.(Angiotech Pharmaceuticals Inc. begins second phase of rheumatoid arthritis treatment trials)(Brief Article)
November 6, 2002... 2002 NOV 6 - (NewsRx.com & NewsRx.net) -- Angiotech Pharmaceuticals Inc. (NASDAQ:ANPI; TSX:ANP) announced that it has initiated a phase II clinical study for the use of Paxceed (Micellar Paclitaxel for Injection) in the treatment of patients...

Data submitted to FDA supporting use of Enbrel.(Amgen Inc. submits etanercept rheumatoid arthritis treatment data)
November 6, 2002... 2002 NOV 6 - (NewsRx.com & NewsRx.net) -- Amgen (NASDAQ:AMGN) announced that it has submitted a supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) for the use of Enbrel (etanercept) to improve...

Manufacturing, supply agreement struck with Biochemie.(and Celltech Group PLC)
November 6, 2002... 2002 NOV 6 - (NewsRx.com & NewsRx.net) -- Celltech Group plc (CLL) announced that it has entered into a long-term agreement with Biochemie, an affiliate of Novartis AG (NVS), under which Biochemie will manufacture for and supply to Celltech...

Chemicon International launches new tissue array instrument.(ATA100 Advanced Tissue Arrayer)
November 6, 2002... 2002 NOV 6 - (NewsRx.com & NewsRx.net) -- Chemicon International, Inc., a leading provider of immunological and molecular biology reagents and tests, announced the launch of the ATA100 Advanced Tissue Arrayer. The ATA100 provides...

Allergic to your DNA?(possible cause of autoimmune disorders)
November 13, 2002... 2002 NOV 13 - (NewsRx.com & NewsRx.net) -- Scientists have discovered that the presence of undigested DNA left over from dead cells can elicit an immune response in the fruit fly Drosophila, prompting researchers to question whether an...

New compound holds promise for lupus and related diseases.(Bz-423 benzodiazepine compound)
November 13, 2002... 2002 NOV 13 - (NewsRx.com & NewsRx.net) -- A chemical cousin of antianxiety medications, such as Valium and Xanax, significantly reduces kidney inflammation in mice inbred to develop a disease resembling human systemic lupus erythematosus...

Alpha particle immunotherapy collaboration formed.(Actinium Pharmaceuticals Inc. has research agreement with Memorial Sloan-Kettering Cancer Center)
November 13, 2002... 2002 NOV 13 - (NewsRx.com & NewsRx.net) -- Actinium Pharmaceuticals, Inc., (API) announced its collaboration with Memorial Sloan-Kettering Cancer Center (MSKCC) in the field of alpha particle immunotherapy (APIT) by signing a license,...

Cytokine imbalance detected in livers of fulminant hepatitis B patients.
November 13, 2002... 2002 NOV 13 - (NewsRx.com & NewsRx.net) -- by Sonia Nichols, senior medical writer - Cellular factors that control the body's response to infection tend to become imbalanced in the livers of hepatitis B virus (HBV)-infected patients, new...

Fellowship funds study of dendritic cell role in immune response.(American Foundation for AIDS Research )
November 13, 2002... 2002 NOV 13 - (NewsRx.com & NewsRx.net) -- The American Foundation for AIDS Research (amfAR) has awarded Emory microbiologist Sang-Moo Kang, PhD, a fellowship to study how dendritic cells might be used to improve the immune response against...

Interaction of novel DNA structures and immune system activation studied.(by Hybridon Inc. )
November 13, 2002... 2002 NOV 13 - (NewsRx.com & NewsRx.net) -- Hybridon, Inc., (HYBN.OB) announced the publication of two articles presenting the results of murine cell culture experiments conducted by Hybridon involving the relationships between novel DNA...

New food allergy test to be developed.(Biomerica Inc. has development contract with Kyowa Medex Company Ltd.)(Brief Article)
November 13, 2002... 2002 NOV 13 - (NewsRx.com & NewsRx.net) -- Biomerica, Inc., (BMRA) a global medical technology company, announced that it has been contracted to develop a new food allergy test for the Kyowa Medex Company, Tokyo, Japan, a subsidiary of Kyowa...

Pharmaceutical company names new president and chief executive officer.(Dey Laboratories Inc. appoints Mel Engle)(Brief Article)
November 13, 2002... 2002 NOV 13 - (NewsRx.com & NewsRx.net) -- Dey, L.P., a specialty pharmaceutical company focused on prescription drug products for the treatment of selected respiratory diseases and allergies, announced the appointment of Mel Engle as the...

Foundation launches first nationwide public service announcement campaign.(Arthritis Foundation)(Brief Article)
November 13, 2002... 2002 NOV 13 - (NewsRx.com & NewsRx.net) -- The Arthritis Foundation in the United States has launched its first nationwide, multimedia public service announcement (PSA) campaign to raise awareness of the nation's number one cause of disability....

FDA approves Anti-R7V diagnostic kit as determinant for progression to AIDS.(URRMA Biopharma Inc.)
November 13, 2002... 2002 NOV 13 - (NewsRx.com & NewsRx.net) -- URRMA Biopharma, Inc., announced the U.S. Food and Drug Administration (FDA) has granted approval of URRMA's investigational device exemption (IDE) application for the Anti-R7V Diagnostic Kit. ...

RNA drug technology shows therapeutic promise against bioterror agents.(HemispheRx Biopharma Inc. announces research agreement with U.S. National Institutes of Health)
November 13, 2002... 2002 NOV 13 - (NewsRx.com & NewsRx.net) -- Hemispherx Biopharma, Inc., (HEB), announced initial results of a new research collaborative agreement with the U.S. National Institutes of Health (NIH) designed to evaluate promising new experimental...

Monoclonal antibody production agreement signed.(Crucell N.V. and Applied Molecular Evolution Inc. to evaluate monoclonal antibody production )(Brief Article)
November 13, 2002... 2002 NOV 13 - (NewsRx.com & NewsRx.net) -- Dutch antibody and vaccine company Crucell N.V. (Euronext, Nasdaq: CRXL) and San Diego, California-based Applied Molecular Evolution, Inc., (AME) (AMEV) announced that they have signed a nonexclusive,...

Operating expenses increase 25% in line with new product development for anticancer drug company.(Antisoma PLC)
November 13, 2002... 2002 NOV 13 - (NewsRx.com & NewsRx.net) -- Antisoma plc (ASOM), the biopharmaceutical company developing new drugs for cancer, announced its preliminary results for the year ended June 30, 2002. Commenting on the results, Glyn Edwards, CEO...

Patents awarded in U.S., Australia for multivalent antibody therapy.(Immunomedics Inc. receives patent for infectious disease treatment)
November 13, 2002... 2002 NOV 13 - (NewsRx.com & NewsRx.net) -- Immunomedics, Inc., (IMMU) announced the issuance of U.S. Patent No. 6,458,933, which corresponds to Australia patent 742,626 issued May 2, 2002, covering new therapy agents for treating infectious...

Novel antibody target identified for potential treatment.(Deltagen Inc. to study DT0441 antibody for use in inflammatory disease treatment)(Brief Article)
November 13, 2002... 2002 NOV 13 - (NewsRx.com & NewsRx.net) -- Deltagen, Inc., (DGEN) announced the discovery of a novel drug target, designated DT044I, for the potential treatment of inflammatory disorders, including rheumatoid arthritis. This target flows...

Experts recommend that asthmatics get flu shot.
November 13, 2002... 2002 NOV 13 - (NewsRx.com & NewsRx.net) -- People with asthma should get a flu shot this fall to help prevent asthma attacks during flu season, the American Lung Association (ALA) recommends. Although the flu poses a major health risk to...

Genemax Corp. files naked short selling lawsuit.(Brief Article)
November 13, 2002... 2002 NOV 13 - (NewsRx.com & NewsRx.net) -- Genemax Corp. (GMXX, Frankfurt:GX1) announced that it has filed a lawsuit against various broker-dealers, market makers, and clearing agents involved in the continued unlawful naked short sales of GMXX...

Collaboration announced for experimental vaccine.(Aastrom Biosciences Inc. and Leland Stanford Junior University to study multiple myeloma vaccine)
November 13, 2002... 2002 NOV 13 - (NewsRx.com & NewsRx.net) -- Aastrom Biosciences, Inc., (ASTM) announced the initiation of a collaborative agreement with Leland Stanford Junior University (Stanford) for an immunotherapeutic vaccine clinical study for multiple...

Patent advances intellectual property of diagnostic imaging, therapeutic products company.(Immunomedics Inc. )
November 13, 2002... 2002 NOV 13 - (NewsRx.com & NewsRx.net) -- Immunomedics, Inc., (IMMU) announced the issuance of a new U.S. Patent No. 6,399,068, which covers therapeutic bispecific antibodies for the treatment of cancers, especially B-cell malignancies, such...

Adalimumab available to patients in need who have failed usual treatments.(Abbott Laboratories announces anti-rheumatic drug availability)
November 13, 2002... 2002 NOV 13 - (NewsRx.com & NewsRx.net) -- Abbott Laboratories announced the initiation of a study to make its investigational medication, D2E7 (adalimumab), available to rheumatoid arthritis (RA) patients in need of additional treatment...

Abbott Laboratories awards scholarships to academic researchers.(Abbott Scholar Award in Rheumatology Research )
November 13, 2002... 2002 NOV 13 - (NewsRx.com & NewsRx.net) -- Abbott Laboratories (NYSE:ABT) has awarded the first Abbott Scholar Award in Rheumatology Research, a mentored research award to help develop future leaders in academic rheumatology, to recipients...

FDA advisers recommend that trials go forward for bubble boy disease.(severe combined immunodeficiency)
November 13, 2002... 2002 NOV 13 - (NewsRx.com & NewsRx.net) -- Gene therapy that seems to cure an often fatal immune disorder also likely gave a French toddler a leukemia-like illness, but U.S. scientists want the genetic experiments restarted anyway - calling the...

Phase I/II study of antiphospholipid syndrome immunotherapeutic discussed.
November 13, 2002... 2002 NOV 13 - (NewsRx.com & NewsRx.net) -- La Jolla Pharmaceutical Company (LJPC) discussed the design and progress of its ongoing phase I/II clinical trial of LJP 1082 for the treatment of antibody-mediated thrombosis at the 10th International...

Study shows why some immune systems control HIV.
November 20, 2002... 2002 NOV 20 - (NewsRx.com & NewsRx.net) -- Scientists are beginning to change their thinking about why the immune systems of most people infected with HIV cannot control the spread of the virus while the immune systems of a rare group of...

New hope for vaccine to fight RA, other autoimmune disorders.
November 20, 2002... 2002 NOV 20 - (NewsRx.com & NewsRx.net) -- Promising animal test results that could lead to a vaccine to fight rheumatoid arthritis, multiple sclerosis (MS) and other autoimmune diseases were announced by researchers at the Technion-Israel...

Angiogenic imbalance may drive pathogenesis of bronchial asthma.
November 20, 2002... 2002 NOV 20 - (NewsRx.com & NewsRx.net) -- by Sonia Nichols, senior medical writer - Scientists have concluded an angiogenic imbalance may impart a role in the pathogenesis of bronchial asthma. "Angiogenesis has recently attracted...

Novel DNA molecules are potent, selective immunoregulators.
November 20, 2002... 2002 NOV 20 - (NewsRx.com & NewsRx.net) -- Hybridon, Inc., (HYBN) announced that its researchers have published data on novel DNA molecules that stimulate the immune system with increased potency and selectivity. These molecules, which use...

Steroid tapering after liver transplant affects hepatitis C recurrence.
November 20, 2002... 2002 NOV 20 - (NewsRx.com & NewsRx.net) -- by Sonia Nichols, senior medical writer - The way steroid dosages are lowered in liver transplantation recipients can markedly affect hepatitis C virus (HCV) severity and recurrence. In fact,...

Interleukin-10 gene suppresses inflammation in opportunistic infection.
November 20, 2002... 2002 NOV 20 - (NewsRx.com & NewsRx.net) -- by Sonia Nichols, senior medical writer - Interleukin-10 gene therapy can quell inflammation stemming from host response to Pneumocystis carinii infection. The news may be important for...

Line of cold and allergy products for children is expanded.
November 20, 2002... 2002 NOV 20 - (NewsRx.com & NewsRx.net) -- First Horizon Pharmaceutical Corporation (NASDAQ:FHRX) announced that it has launched two line extensions to its Tanafed line of pediatric products to relieve cold and allergy symptoms. The line...

Pharmaceutical company announces additions to senior management.
November 20, 2002... 2002 NOV 20 - (NewsRx.com & NewsRx.net) -- La Jolla Pharmaceutical Company (NASDAQ:LJPC) announced that it has appointed David Duncan, Jr. to the position of chief financial officer and Karen Church, RAC, to the position of vice president of...

Laser research yields precision breath analysis tool for diagnosis.
November 20, 2002... 2002 NOV 20 - (NewsRx.com & NewsRx.net) -- Research at the University of Oklahoma has yielded a novel way of using a laser to analyze exhalations of asthma sufferers, opening the door to more accurate diagnosis and prescriptive treatment of the...

New CDC report proposes strategies to help schools manage asthma.
November 20, 2002... 2002 NOV 20 - (NewsRx.com & NewsRx.net) -- A report from the U.S. Centers for Disease Control and Prevention (CDC) outlines six strategies to help the nation's schools manage the problems of students with asthma. The guide, Strategies for...

Research center awarded $7 million grant to lead research initiative.
November 20, 2002... 2002 NOV 20 - (NewsRx.com & NewsRx.net) -- The Leukemia & Lymphoma Society announced it has awarded a $7 million grant through its Specialized Center of Research (SCOR) program to Dr. Irwin Bernstein, head of pediatric oncology research at the...

Anticancer antibody developer signs agreement with Protein Design Labs, Inc.
November 20, 2002... 2002 NOV 20 - (NewsRx.com & NewsRx.net) -- Arius Research, Inc., (TSX-VE: YAR) has entered into a collaborative research agreement with Protein Design Labs, Inc., (NASDAQ:PDLI) to evaluate two novel anticancer antibodies developed by Arius. ...

License option agreement signed for cancer epitopes for ex vivo applications.
November 20, 2002... 2002 NOV 20 - (NewsRx.com & NewsRx.net) -- Epimmune, Inc., (NASDAQ:EPMN) a biotechnology company focused on the development of pharmaceutical products using multiple, specific epitopes to activate the body's immune system, announced that it had...

System to administer medications has several applications.
November 20, 2002... 2002 NOV 20 - (NewsRx.com & NewsRx.net) -- Aradigm Corporation (NASDAQ:ARDM) announced financial results for the third quarter and 9 months ended September 30, 2002, highlighting some of the company's programs. The company's AERx system is...

Pregabalin successfully addresses pain.
November 20, 2002... 2002 NOV 20 - (NewsRx.com & NewsRx.net) -- by Lynn Yoffee, senior medical writer - In the largest randomized, placebo-controlled trial of a monotherapy for fibromyalgia to date, investigators have found that a new agent, pregabalin,...

Drug manufacturers settle royalty payment arbitration.
November 20, 2002... 2002 NOV 20 - (NewsRx.com & NewsRx.net) -- Biogen, Inc., (NASDAQ:BGEN) announced that it has settled its arbitrations with Schering-Plough Corporation over royalties on U.S. sales of alpha interferon products. As part of the settlement,...

Intervention program shows success.
November 20, 2002... 2002 NOV 20 - (NewsRx.com & NewsRx.net) -- Targeting an at-risk population through interactive education may result in a significantly reduced chance of contracting Lyme disease, according to research presented at the recent American College of...

Pharmaceutical company to acquire developer of autoinjection technology.
November 20, 2002... 2002 NOV 20 - (NewsRx.com & NewsRx.net) -- King Pharmaceuticals, Inc., (NYSE:KG) and Meridian Medical Technologies, Inc., (NASDAQ:MTEC) announced that they have entered into a definitive agreement whereby King will acquire Meridian for a cash...

Product line application launched to facilitate MAb therapy development.
November 20, 2002... 2002 NOV 20 - (NewsRx.com & NewsRx.net) -- IGEN International, Inc., (NASDAQ:IGEN) announced that it has launched a new application of its proprietary Origen technology for use by pharmaceutical and biotechnology researchers involved in...

Agennix, DSM open manufacturing facility in Italy.
November 20, 2002... 2002 NOV 20 - (NewsRx.com & NewsRx.net) -- Agennix, Inc., and DSM Pharmaceutical Products, a business group of DSM, N.V., jointly announced the opening of a new manufacturing facility on DSM's fermentation site in Capua, Italy. The...

Cancer drug may be useful treatment.
November 20, 2002... 2002 NOV 20 - (NewsRx.com & NewsRx.net) -- Rituximab may treat rheumatoid arthritis in novel way by more selectively targeting the B cells, which make antibodies that contribute to the disease process, according to research presented at the...

Costimulation blocker introduced as promising new treatment route.
November 20, 2002... 2002 NOV 20 - (NewsRx.com & NewsRx.net) -- by Lynn Yoffee, senior medical writer - A new biologic treatment for rheumatoid arthritis has been shown to improve response rate in patients when administered with methotrexate, one of the...

HuMax-CD4 in combination therapy not effective.
November 20, 2002... 2002 NOV 20 - (NewsRx.com & NewsRx.net) -- Genmab A/S announced results from the initial stage of the phase II clinical trial involving 155 patients with active rheumatoid arthritis (RA). At the primary endpoint of the study in week 7 there...

Early exposure to other children increases risk.(of childhood asthma)
November 27, 2002... 2002 NOV 27 - (NewsRx.com & NewsRx.net) -- Children who live with several siblings or who go to nurseries have less hay fever but more asthma as adults, suggests a large international study in Thorax. The findings are based on interviews...

Immune synapses cannot function without ZAP-70.(severe combined immune deficiency caused by enzyme anomalies)
November 27, 2002... 2002 NOV 27 - (NewsRx.com & NewsRx.net) -- A familial form of severe combined immune deficiency (SCID) is caused by anomalies of an enzyme called ZAP-70. If ZAP-70 is lacking or does not work, the T-cells, which play a key role in the...

TNF-alpha shows high clinical efficacy, regression of spinal inflammation.(antitumor necrosis factor alpha therapy with infliximab (Remicade) aids in ankylosing spondylitis regression)
November 27, 2002... 2002 NOV 27 - (NewsRx.com & NewsRx.net) -- Data presented at the 2002 annual meeting of the American College of Rheumatology (ACR) showed treatment with the antitumor necrosis factor alpha (TNF-alpha) therapy infliximab (also known as Remicade)...

UCSD cancer researchers develop new antileukemia strategy.(leukemia cells and immune-system T cells are combined to create a cancer-killing cocktail)
November 27, 2002... 2002 NOV 27 - (NewsRx.com & NewsRx.net) -- Cancer researchers at the University of California, San Diego (UCSD) have developed a three-step process in which human leukemia cells and neighboring immune-system T cells are manipulated together in...

Research report shows new approach to replacing immune cells to shrink tumors.(metastatic melanoma treatment)
November 27, 2002... 2002 NOV 27 - (NewsRx.com & NewsRx.net) -- A new approach to cancer treatment that replaces a patient's immune system with cancer-fighting cells can lead to tumor shrinkage, researchers reported in the journal Science. The study...

Adalimumab (D2E7) phase III data reported.(Abbott Laboratories reports on Humira)
November 27, 2002... 2002 NOV 27 - (NewsRx.com & NewsRx.net) -- Abbott Laboratories presented data from pivotal phase III and ongoing clinical trials of Humira (adalimumab). Humira, also known as D2E7, is Abbott Laboratories' investigational fully human...

Patient participation is an effective, low-cost measure to improve outcomes.(in systemic lupus erythematosus care)
November 27, 2002... 2002 NOV 27 - (NewsRx.com & NewsRx.net) -- by Lynn Yoffee, senior medical writer - Systemic lupus erythematosus (SLE) patients who participate more actively in their healthcare are more likely to have less morbidity and better outcomes overall,...

Tablet-based immunotherapy agreement announced.(between ALK-Abello and Schering-Plough Corp.)(Brief Article)
November 27, 2002... 2002 NOV 27 - (NewsRx.com & NewsRx.net) -- ALK-Abello and Schering-Plough Corporation (SGP) announced an agreement to collaborate in conducting a clinical trial of an ALK-Abello tablet-based immunotherapy for the treatment of allergy symptoms...

Neuroinflammatory disease preclinical research published.(by Vasogen Inc. )
November 27, 2002... 2002 NOV 27 - (NewsRx.com & NewsRx.net) -- Vasogen, Inc., (VSV) a developer of immune modulation therapies for inflammatory conditions, announced that previously reported results from preclinical studies in neuroinflammation, an underlying...

HuMax-CD20 program targets lymphomas and autoimmune diseases.(non-Hodgkin lymphoma treatment from Genmab A/S)
November 27, 2002... 2002 NOV 27 - (NewsRx.com & NewsRx.net) -- Genmab A/S has announced its new HuMax-CD20 program. Antibodies in this program target the CD20 antigen on B cells and initially Genmab will focus on using the antibody for the treatment of...

Data confirm gastrointestinal safety profile of COX-2 specific inhibitor.(Bextra (valdecoxib) safe for rheumatoid arthritis treatment)
November 27, 2002... 2002 NOV 27 - (NewsRx.com & NewsRx.net) -- Analyses of pooled study results for the COX-2 specific inhibitor Bextra (valdecoxib tablets), presented at the 2002 annual scientific meeting of the American College of Rheumatology (ACR), indicate...

HHS awards University of Wisconsin $55.8 million for research.(on childhood asthma )
November 27, 2002... 2002 NOV 27 - (NewsRx.com & NewsRx.net) -- U.S. Health and Human Services Secretary Tommy G. Thompson has announced that the National Institute of Allergy and Infectious Diseases (NIAID) has awarded a 6-year, $55.8 million contract to the...

New research explores cost-effectiveness of inner-city intervention programs.(prevention of childhood asthma complications)
November 27, 2002... 2002 NOV 27 - (NewsRx.com & NewsRx.net) -- Using social workers to educate inner-city children on controlling their asthma is a cost-effective way to reduce the number of days children exhibit asthma symptoms, researchers report. ...

QVAR touted to patients who previously used Vanceril.(IVAX Corp. reports that beclomethasone dipropionate is a viable alternative for asthma treatment)(Brief Article)
November 27, 2002... 2002 NOV 27 - (NewsRx.com & NewsRx.net) -- The half-million patients using Vanceril (beclomethasone dipropionate CFC) to control their asthma symptoms are learning that the product is no longer being manufactured. Schering-Plough...

rhAFP clinical production set to begin.(GTC Biotherapeutics Inc. and Merrimack Pharmaceuticals Inc. to produce ABI.001 recombinant human alpha-fetoprotein )
November 27, 2002... 2002 NOV 27 - (NewsRx.com & NewsRx.net) -- GTC Biotherapeutics, Inc. (GTCB) and Merrimack Pharmaceuticals, Inc. signed a letter of intent to begin production of Merrimack's ABI.001, a recombinant human alpha-fetoprotein (rhAFP), to be used in...

Unlabeled CEA antibody inhibits human tumor growth, enhances drug effects.(carcinoembryonic antigen inhibits medullary thyroid cancer growth)
November 27, 2002... 2002 NOV 27 - (NewsRx.com & NewsRx.net) -- Immunomedics, Inc. (IMMU) announced that preclinical studies involving its proprietary unlabeled antibody, which targets carcinoembryonic antigen (CEA), demonstrated antitumor activity in animals with...

Dosage confirmed for antisense drug in small phase II trial.(alicaforsen (ISIS 2302) antisense drug may produce remission in Crohn disease)
November 27, 2002... 2002 NOV 27 - (NewsRx.com & NewsRx.net) -- Results of an open-label, phase II clinical trial of alicaforsen (ISIS 2302) in patients with Crohn disease show that the antisense drug may produce clinical disease remissions when patients receive...

JNK inhibitor beginning phase I clinical trial.(c-Jun N-terminal Kinase inhibitor, CC-401, to be tested by Celgene Corp. )(Brief Article)
November 27, 2002... 2002 NOV 27 - (NewsRx.com & NewsRx.net) -- Celgene Corporation (CELG) announced that it advanced its lead JNK (c-Jun N-terminal Kinase) inhibitor, CC-401, into clinical testing. The recently initiated phase I, double-blind,...

First findings presented from phase II pemtumomab trial.(Antisoma PLC reports on gastric cancer therapy trial)(Brief Article)
November 27, 2002... 2002 NOV 27 - (NewsRx.com & NewsRx.net) -- Antisoma plc, a U.K.-based biopharmaceutical company, announced that preliminary findings from its pilot phase II trial of pemtumomab in gastric cancer were presented at the Ninth Conference on Cancer...

Biotech company says its scientists have created new molecules.(Maxygen Inc.)("Chimeric Costimulatory Molecules That Selectively Act Through CD28 or CTLA-4 on Human T Cells" )
November 27, 2002... 2002 NOV 27 - (NewsRx.com & NewsRx.net) -- Maxygen, Inc., (MAXY) announced that its scientists have created a series of molecules that could be used to treat a variety of diseases including cancer, infectious diseases, and autoimmune diseases....